|
| Press Releases |
|
 |
|
| Thursday, July 31, 2025 |
|
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
|
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the latest findings demonstrating the benefits of continuous treatment with lecanemab-irmb (U.S. brand name: LEQEMBI(R)), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada, and virtually more info >> |
|
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
|
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai")and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher,"Biogen") announced today that results on investigational maintenance therapy with subcutaneous autoinjector (SCAI) of lecanemab-irmb (U.S. brand name: LEQEMBI(R)), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference(AAIC) 2025, held in Toronto, and virtually. more info >> |
|
|
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI(R)), an anti-AB protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually more info >> |
|
| Tuesday, July 29, 2025 |
|
|
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its in-house discovered tyrosine kinase inhibitor, "LENVIMA(R)" (generic name: lenvatinib mesylate), in combination with the anti-PD-1 antibody, pembrolizumab, and transarterial chemoembolization (TACE) has been approved by the National Medical Products Administration (NMPA) of China for unresectable, non-metastatic hepatocellular carcinoma. more info >> |
|
| Friday, July 25, 2025 |
|
|
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has been included in the FTSE4Good Index Series for the 24th consecutive year since its initial inclusion in 2002. more info >> |
|
| Wednesday, July 23, 2025 |
|
|
Launch of Beova(R) Tablets in Thailand for Overactive Bladder |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and KYORIN Pharmaceutical Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, President and CEO: Yutaka Ogihara, "KYORIN") announced today that Eisai (Thailand) Marketing Co., Ltd. ("Eisai Thailand"), a subsidiary of Eisai, has launched overactive bladder treatment Beova(R) Tablets (generic name vibegron) in Thailand more info >> |
|
| Tuesday, July 22, 2025 |
|
|
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings from its robust Alzheimer's disease (AD) pipeline and research, including our dual-acting, anti-amyloid beta (AB;) protofibril antibody for the treatment of AD, lecanemab (generic name, U.S. brand name: LEQEMBI(R)), and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer's Association International Conference (AAIC), being held in Toronto and virtually from July 27-31. more info >> |
|
| Wednesday, July 16, 2025 |
|
|
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the drug discovery research for Lecanemab (product name: "LEQEMBI"), a humanized anti-human soluble amyloid B (AB) protofibril monoclonal antibody indicated for early Alzheimer's disease (early AD*), which was co-developed by Eisai and BioArctic AB (Headquarters: Sweden; herein after, BioArctic), has received "The 9th Bioindustry Award" from the Japan Bioindustry Association (JBA). more info >> |
|
|
エーザイ、抗アミロイドβ抗体レカネマブの創薬研究が「第 9 回バイオインダストリー大賞」を受賞 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、当社と BioArctic AB（本社：スウェーデン、以下 バイオアークティック）が創製した早期アルツハイマー病（早期 AD*）を適応とする、ヒト化抗ヒト可溶性アミロイドβ（Aβ）凝集体（プロトフィブリル）モノクローナル抗体レカネマブ（製品名：「レケンビ®」）の創薬研究が、一般財団法人バイオインダストリー協会より「第 9 回 バイオインダストリー大賞」を受賞したことをお知らせします。 more info >> |
|
| Monday, July 14, 2025 |
|
|
"URECE" (Dotinurad) Launched in China as a treatment for Gout |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has launched "URECE" (brand name in China: "Youlesi", generic name: dotinurad) in China as a treatment for Gout. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Datavault AI CEO Nathaniel T. Bradley to Deliver Flagship Keynotes on Breakthrough RWA Tokenization at CONV3RGENCE London and AssetRush x Zurich 2026
Apr 7, 2026 11:06 HKT/SGT
|
|
|
Datavault AI CEO Nathaniel T. Bradley to Deliver Flagship Keynotes on Breakthrough RWA Tokenization at CONV3RGENCE London and AssetRush x Zurich 2026
Apr 6, 2026 23:00: JST
|
|
|
Datavault AI 執行長納撒尼爾·T·布拉德利將於 CONV3RGENCE London 及 AssetRush × Zurich 2026 大會發表關於 RWA 代幣化突破性進展的旗艦主題演講
Apr 6, 2026 22:00 HKT/SGT
|
|
|
Datavault AI 首席执行官内森尼尔·T·布拉德利将在 CONV3RGENCE 伦敦峰会及 AssetRush × 苏黎世 2026 峰会上发表关于 RWA 代币化突破性进展的主题演讲
Apr 6, 2026 22:00 HKT/SGT
|
|
|
Honda、「N-BOX」が2025年度 新車販売台数 第1位を獲得
Apr 6, 2026 16:00: JST
|
|
|
JFEと三菱商事、京浜扇島地区における電力事業とデータセンター事業を一体とした共同事業について基本合意書締結
Apr 6, 2026 15:30: JST
|
|
|
JFE Holdings and Mitsubishi Corporation Sign Second MOU to Advance Integrated Power and Data Center Project in Ohgishima, Keihin District
Apr 6, 2026 14:27 JST
|
|
|
The Full Spectrum of K-Culture in One Place: "2026 MyK FESTA" to Open June 25
Apr 3, 2026 23:00: JST
|
|
|
The Full Spectrum of K-Culture in One Place: "2026 MyK FESTA" to Open June 25
Apr 3, 2026 23:00 HKT/SGT
|
|
|
海通恒信2025年報：協同效應加速釋放 新興賽道引領結構升級
Apr 3, 2026 20:28 HKT/SGT
|
|
|
海通恒信2025年报：协同效应加速释放 新兴赛道引领结构升级
Apr 3, 2026 19:43 HKT/SGT
|
|
|
新希望乳業攜手香港十字牌 借道本土老字號共拓港澳市場
Apr 3, 2026 16:51 HKT/SGT
|
|
|
新希望乳业携手香港十字牌 借道本土老字号共拓港澳市场
Apr 3, 2026 16:44 HKT/SGT
|
|
|
新希望乳業與香港十字牌達成戰略合作：雙方充分發揮資源稟賦 助力港澳乳品行業高質量發展
Apr 3, 2026 16:38 HKT/SGT
|
|
|
新希望乳业与香港十字牌达成战略合作：双方充分发挥资源禀赋 助力港澳乳品行业高质量发展
Apr 3, 2026 16:26 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
